Otello Stampacchia is a partner at Omega Funds where he has had particular recent involvement in investments in Micromet, BioVex, Juno and Jounce Therapeutics. Previously, Otello was in charge of life sciences direct investments at AlpInvest Partners, one of the largest private equity asset managers worldwide. At AlpInvest, Otello was responsible for the direct life sciences investments, as well as assisting in due diligence for healthcare venture fund of funds investments. Before AlpInvest, Otello was the portfolio manager of the Lombard Odier Immunology Fund, a $3bn listed investment vehicle, investing in public and private healthcare companies worldwide. Previously, Otello was a member of the HealthCare corporate finance and M&A team at Goldman Sachs. Before joining Goldman, Otello helped co-found the healthcare investment activities at Index Securities (now Index Ventures). Otello has a PhD in Molecular Biology from the University of Geneva (Switzerland), and a PhD in Biotechnology.